Contrave is an FDA-approved weight management medication that combines two existing drugs — naltrexone (an opioid blocker used in addiction treatment) and bupropion (an antidepressant used for smoking cessation) — in a single extended-release tablet. The combination works through a unique mechanism that targets the brain's reward and hunger-control centers simultaneously, making it particularly effective for patients whose weight gain is driven by emotional eating, food addiction patterns, or strong food cravings.
Unlike GLP-1 medications which primarily reduce appetite through gut-brain hormone signaling, Contrave works by modulating the hypothalamus and mesolimbic dopamine system — areas of the brain responsible for reward, motivation, and addictive behavior. Naltrexone blocks opioid receptors that contribute to the pleasure response from eating, while bupropion activates receptors in the hypothalamus and mesolimbic system to reduce appetite and cravings.
In clinical trials, Contrave produced an average weight loss of 5–9% of body weight over 56 weeks. While less than the weight loss seen with GLP-1 medications, Contrave is often preferred for patients with strong emotional eating patterns, depression, or a history of food addiction, as bupropion's antidepressant properties may provide additional psychological benefits alongside weight management.
